

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This is to inform you of a product recall by **Merck for Belsomra (suvorexant) tablets, for oral use, C-IV, (3 x 10 single dose 10mg tablets in 1 carton)**

Merck initiated a voluntary recall of lots **2090019** and **2123744** of BELSOMRA® (suvorexant) 10mg tablets because of the potential for delayed dissolution of the dose after administration.

The lots were distributed by Merck between November 19, 2024 and February 27, 2025. The potential medical concern is that the delayed dissolution of a non-conforming tablet may result in a delayed release of the active ingredient thereby delaying the onset of sleep for a patient being treated for insomnia.

| Lot | Expiry |
|---------|-----------|
| 2090019 | 30APR2027 |
| 2123744 | 30APR2027 |